Polypharmacy and drug-drug interactions among patients with Diabetes Mellitus

Filiz Özyiğit; Türkan Paşalı Kilit; Kevser Onbaşı

Makale detayları

Polypharmacy and drug-drug interactions among patients with Diabetes Mellitus

Yazarlar:

Filiz Özyiğit | Türkan Paşalı Kilit | Kevser Onbaşı

Yayıncı:

Bandirma Onyedi Eylul University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Hipokrat Tıp Dergisi Vol.3 Issue 3, pp.7-15

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001305589

pISSN:

2791-9935

Anahtar kelimeler:

Özet:

 Background: Diabetes mellitus is a chronic disease. The aim of our study was to evaluate drug- drug interactions and polypharmacy in diabetic patients. Methods: Patients with type 2 diabetes attending our internal medicine and endocrinology policlinics from April 2019 to July 2019 were included to the study. It was designed as a prospective, descriptive and cross-sectional study. The socio-demographic characteristics of diabetic individuals, the drugs they use in the treatment of diabetes, and other accompanying diseases were evaluated according to the ATC classification. In this study, interactions between multiple drugs and polypharmacy were examined. Results: The study population consisted of 526 patients between the ages of 18-87years 59  11. 69.6 of the patients were women.83.8 of the patients had chronic diseases accompanying diabetes. The most common chronic diseases were hypertension 53.6, hyperlipidemia 41.4 and coronary artery disease 27.2, respectively. 45.01 of the patients were using five or more drugs. The mean number of drugs was found to be 4.49  1.93. Among the drugs used by the patients, 787 drug-drug interactions were found in a total of 429 81.5 patients. The average number of interactions was 3.89  3.6 for interaction A 15.2 n  81, 16.2 n  85 for interaction B, 69.8 n  367 for interaction C was, 47.9 n  252 for interaction D, and 0.4 n  2 for interaction X. The most frequent interaction was found between acetylsalicylic acid and insulin and metformin and angiotensin converting enzyme inhibitors. Conclusions: Both the polypharmacy rate and drug-drug interaction rate are high in diabetic patients. The most common type of interaction is type C and type D drug-drug interaction. Attention should be paid to drug-drug interactions in the treatment of diabetes patients.

 Background: Diabetes mellitus is a chronic disease. The aim of our study was to evaluate drug- drug interactions and polypharmacy in diabetic patients. Methods: Patients with type 2 diabetes attending our internal medicine and endocrinology policlinics from April 2019 to July 2019 were included to the study. It was designed as a prospective, descriptive and cross-sectional study. The socio-demographic characteristics of diabetic individuals, the drugs they use in the treatment of diabetes, and other accompanying diseases were evaluated according to the ATC classification. In this study, interactions between multiple drugs and polypharmacy were examined. Results: The study population consisted of 526 patients between the ages of 18-87years 59  11. 69.6 of the patients were women.83.8 of the patients had chronic diseases accompanying diabetes. The most common chronic diseases were hypertension 53.6, hyperlipidemia 41.4 and coronary artery disease 27.2, respectively. 45.01 of the patients were using five or more drugs. The mean number of drugs was found to be 4.49  1.93. Among the drugs used by the patients, 787 drug-drug interactions were found in a total of 429 81.5 patients. The average number of interactions was 3.89  3.6 for interaction A 15.2 n  81, 16.2 n  85 for interaction B, 69.8 n  367 for interaction C was, 47.9 n  252 for interaction D, and 0.4 n  2 for interaction X. The most frequent interaction was found between acetylsalicylic acid and insulin and metformin and angiotensin converting enzyme inhibitors. Conclusions: Both the polypharmacy rate and drug-drug interaction rate are high in diabetic patients. The most common type of interaction is type C and type D drug-drug interaction. Attention should be paid to drug-drug interactions in the treatment of diabetes patients.

 Background: Diabetes mellitus is a chronic disease. The aim of our study was to evaluate drug- drug interactions and polypharmacy in diabetic patients. Methods: Patients with type 2 diabetes attending our internal medicine and endocrinology policlinics from April 2019 to July 2019 were included to the study. It was designed as a prospective, descriptive and cross-sectional study. The socio-demographic characteristics of diabetic individuals, the drugs they use in the treatment of diabetes, and other accompanying diseases were evaluated according to the ATC classification. In this study, interactions between multiple drugs and polypharmacy were examined. Results: The study population consisted of 526 patients between the ages of 18-87years 59  11. 69.6 of the patients were women.83.8 of the patients had chronic diseases accompanying diabetes. The most common chronic diseases were hypertension 53.6, hyperlipidemia 41.4 and coronary artery disease 27.2, respectively. 45.01 of the patients were using five or more drugs. The mean number of drugs was found to be 4.49  1.93. Among the drugs used by the patients, 787 drug-drug interactions were found in a total of 429 81.5 patients. The average number of interactions was 3.89  3.6 for interaction A 15.2 n  81, 16.2 n  85 for interaction B, 69.8 n  367 for interaction C was, 47.9 n  252 for interaction D, and 0.4 n  2 for interaction X. The most frequent interaction was found between acetylsalicylic acid and insulin and metformin and angiotensin converting enzyme inhibitors. Conclusions: Both the polypharmacy rate and drug-drug interaction rate are high in diabetic patients. The most common type of interaction is type C and type D drug-drug interaction. Attention should be paid to drug-drug interactions in the treatment of diabetes patients.

 Amaç: Diabetes Mellitus kronik bir hastalıktır. Çalışmamızın amacı diyabetik hastalarda ilaç-ilaç etkileşimlerini ve polifarmasiyi değerlendirmektir. Yöntemler: Nisan 2019 ile Temmuz 2019 tarihleri arasında dahiliye ve endokrinoloji polikliniğimize başvuran tip 2 diyabetli hastalar çalışmaya dahil edildi. Prospektif, tanımlayıcı ve kesitsel bir çalışma olarak tasarlandı. Diyabetli bireylerin sosyo-demografik özellikleri, diyabet tedavisinde kullandıkları ilaçlar ve eşlik eden diğer hastalıkları ATC sınıflamasına göre değerlendirildi. Bu çalışmada çoklu ilaç ve polifarmasi arasındaki etkileşimler incelenmiştir. Sonuçlar Araştırmanın evrenini yaşları 18-87yıl 5911 arasında değişen 526 hasta oluşturdu. Hastaların 69,6sı kadındı. Hastaların 83,8inde diyabete eşlik eden kronik hastalıklar vardı. En sık görülen kronik hastalıklar sırasıyla hipertansiyon 53,6, hiperlipidemi 41,4 ve koroner arter hastalığı 27,2 olarak belirlendi. Hastaların 45,01i beş ve daha fazla ilaç kullanıyordu. Ortalama ilaç sayısı ise 4,491,93 olarak belirlendi. Hastaların kullandığı ilaçlardan toplam 429 81,5 hastada 787 ilaç-ilaç etkileşimi tespit edildi. Ortalama etkileşim sayısı 3,89  3,6, etkileşim A için 15,2 n  81, etkileşim B için 16,2 n  85, etkileşim C için 69,8 n  367, 47,9 n  252 idi. etkileşim D için ve etkileşim X için 0,4 n  2. En sık görülen etkileşim asetilsalisilik asit ve insülin ile metformin ve anjiyotensin dönüştürücü enzim inhibitörleri arasında bulundu. Diyabetik hastalarda hem polifarmasi oranı hem de ilaç-ilaç etkileşimi oranı yüksektir. En sık görülen etkileşim türü C tipi ve D tipi ilaç-ilaç etkileşimleridir. Diyabet hastalarının tedavisinde ilaç-ilaç etkileşimlerine dikkat edilmelidir.

Makale detayları

Polypharmacy and drug-drug interactions among patients with Diabetes Mellitus

Yazarlar:

Filiz Özyiğit | Türkan Paşalı Kilit | Kevser Onbaşı

Yayıncı:

Bandirma Onyedi Eylul University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Hipokrat Tıp Dergisi Vol.3 Issue 3, pp.7-15

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001305589

pISSN:

2791-9935

drug-drug interactions

polypharmacy

diabetesDiabetes Mellitus

İlaç ilaç etkileşimleri

polifarmasi

Sayı

Makale detayları

Polypharmacy and drug-drug interactions among patients with Diabetes Mellitus

Yazarlar: Filiz Özyiğit | Türkan Paşalı Kilit | Kevser Onbaşı

Yayıncı: Bandirma Onyedi Eylul University

Ana Başlıklar: Endokrinoloji | İç Hastalıkları

Dergi: Hipokrat Tıp Dergisi Vol.3 Issue 3, pp.7-15

Belge Tipi: Makale

Yayın Tarihi: 12/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001305589

pISSN: 2791-9935

drug-drug interactions

polypharmacy

diabetesDiabetes Mellitus

İlaç ilaç etkileşimleri

polifarmasi

Sayı

Yazarlar:

Filiz Özyiğit | Türkan Paşalı Kilit | Kevser Onbaşı

Yayıncı:

Bandirma Onyedi Eylul University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Hipokrat Tıp Dergisi Vol.3 Issue 3, pp.7-15

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001305589

pISSN:

2791-9935